These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26804639)

  • 1. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
    Bai SA; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
    Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
    Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
    Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
    J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.
    Rauck RL; Potts J; Xiang Q; Tzanis E; Finn A
    Postgrad Med; 2016 Jan; 128(1):1-11. PubMed ID: 26634956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.
    Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
    Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 27933600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole greatly increases the exposure to oral buprenorphine.
    Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
    Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.
    Willsie SK; Evashenk MA; Hamel LG; Hwang SS; Chiang YK; Palmer PP
    Clin Ther; 2015 Jan; 37(1):145-55. PubMed ID: 25544247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
    Vasisht N; Gever LN; Tagarro I; Finn AL
    Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study.
    Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
    Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 22128878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Pharmacokinet; 2005; 44(12):1279-86. PubMed ID: 16372825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.